However, polymorphisms in SH2B3 can impair this regulatory control, leading to dysregulated cytokine signaling and exaggerated inflammatory responses, promoting vascular injury, endothelial dysfunction, and smooth muscle proliferation; therefore, genetic variants have been linked to an increased susceptibility to PAD [42]. Here, SH2B3 is linked to peripheral arterial disease.